Global Fucosidosis Therapeutics Market to Reach USD 17.91 Million by 2033 with a 6% CAGR

Fucosidosis Therapeutics Market

The global Fucosidosis Therapeutics Market is projected to grow significantly, reaching a market value of USD 17.91 Million by 2033, up from USD 10 Million in 2023, according to recent analysis. The market is expected to expand at a Compound Annual Growth Rate (CAGR) of 6% from 2023 to 2033.

Fucosidosis is a rare autosomal recessive lysosomal storage disorder caused by a deficiency in alpha-L-fucosidase, with an estimated occurrence of less than 1 in 200,000 live births. The rising awareness of this condition and advancements in therapeutic development are driving the market’s growth.

Historically, the Fucosidosis Therapeutics market experienced a 4% CAGR from 2018 to 2022, and with increased focus on research, the market is expected to see accelerated progress over the next decade.

According to market research and competitive intelligence provider Future Market Insights- the market for Fucosidosis Therapeutics reflected a value of 4% during the historical period, 2018 to 2022.

A series of international-level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Fucosidosis Therapeutics.

The market’s growth is attributed to the factors such as expanding the area of advanced therapies along with gene delivery technologies and has developed progressive competition among key players focused on the commercialization of their therapies. The biotechnology companies are investing in acquisitions, mergers/collaborations, and expansions as key strategies to increase in-house expertise and strengthen product pipelines.

In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for Fucosidosis Therapeutics. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of fucosidosis is fuelling the market growth. Thus, the market for Fucosidosis Therapeutics is expected to register a CAGR of 6% in the forecast period 2023 to 2033.

Market Competition

Key players in the Fucosidosis Therapeutics Market are Sigma-Aldrich. BD, Enzo Life Sciences, Creative Diagnostics, Thermo Fisher Scientific, Epitope Diagnostics Inc., R&D Systems, QED Bioscience Inc, and ACROBiosystems among other global players.

• In April 2022, Bruker launched a novel MALDI HiPLEX-IHC tissue imaging solution for timsTOF flex using AmberGen’s HiPLEX-IHC peptide code antibody probes, combined with unbiased lipidomics, glycomics, and metabolomics tissue imaging.
• In November 2019, Lonza Group Ltd. partnered with Cryoport, Inc. in the cell and gene therapy field and across Lonza’s ‘vein-to-vein’ delivery network.

Key Companies Profiled

• Sigma-Aldrich. BD
• Enzo Life Sciences
• Creative Diagnostics
• Thermo Fisher Scientific
• Epitope Diagnostics Inc.
• Research and Development Systems
• QED Bioscience Inc
• ACROBiosystems.

A Full Report Overview

Key Segments Profiled in the Fucosidosis Therapeutics Industry Survey

Therapy:

• Antibiotic Therapy
• Fluid Replacement Therapy
• Bone Marrow Transplantation

End-User:

• Hospital
• Homecare
• Specialty Clinics
• Others

Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube